2026-04-13T07:07:37Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/136482025-09-30T02:08:53Zcom_2072_378070com_2072_378040col_2072_378092

Impact of trifluridine/tipiracil plus bevacizumab on tumor shrinkage and depth of response in refractory metastatic colorectal cancer: analysis of the SUNLIGHT trial Modest, Dominik P. Elez, Elena taieb, julien Fakih, Marwan Ciardiello, Fortunato Van Cutsem, Eric Metàstasi Recte - Càncer - Tractament Còlon - Càncer - Tractament Quimioteràpia combinada Avaluació de resultats (Assistència sanitària) ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy Protocols DISEASES::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Intestinal Neoplasms::Colorectal Neoplasms Other subheadings::Other subheadings::Other subheadings::/drug therapy DISEASES::Neoplasms::Neoplastic Processes::Neoplasm Metastasis ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis::Treatment Outcome TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias gastrointestinales::neoplasias intestinales::neoplasias colorrectales Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia ENFERMEDADES::neoplasias::procesos neoplásicos::metástasis neoplásica TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico::resultado del tratamiento Bevacizumab; Colorectal cancer; Depth of response Bevacizumab; Cáncer colorrectal; Profundidad de respuesta Bevacizumab; Càncer colorectal; Profunditat de resposta Objectives: This post hoc analysis of the SUNLIGHT trial sought to assess the response to treatment with trifluridine/tipiracil (FTD/TPI) + bevacizumab and FTD/TPI in patients with refractory metastatic colorectal cancer using tumor shrinkage (TS), early TS (ETS), duration of TS (DTS) and depth of response (DpR) as response-related parameters. Methods: TS was defined as any decrease from baseline of the sum of the longest diameter of target lesions. TS at first assessment was specified as ETS. DpR was defined as the maximum percentage change from baseline of the sum of the longest diameters of target lesions. DTS was defined as the time from first TS to first increase in tumor size, progressive disease, or death. Results: In the FTD/TPI + bevacizumab group, 48 % had TS and 39 % had ETS. In the FTD/TPI group, 21 % had TS and 17 % had ETS. In patients achieving ETS, median DTS was prolonged with FTD/TPI + bevacizumab compared to FTD/TPI (3.8 versus 2.1 months; HR: 0.34 [95 % CI: 0.22, 0.53]; P < 0.0001). Magnitude of DpR was greater with FTD/TPI + bevacizumab than with FTD/TPI. Conclusion: The survival benefit of treatment with FTD/TPI + bevacizumab versus FTD/TPI is likely associated with the improvement of ETS and DpR. This analysis was funded by Institut de Recherches Internationales, Servier, France. 2025-09-30T02:08:53Z 2025-09-30T02:08:53Z 2025-09-30T02:08:53Z 2025-09-16T07:31:42Z 2025-09-16T07:31:42Z 2025-09-09 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://hdl.handle.net/11351/13648 European Journal of Cancer;227 https://doi.org/10.1016/j.ejca.2025.115644 Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ info:eu-repo/semantics/openAccess Elsevier Scientia